Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Diverging from tested vaccination regimens without scientific evidence could undermine public confidence in vaccines against COVID-19 and the success of a global vaccination strategy to curtail the pandemic.
As the number of people with obesity and type 2 diabetes increases around the world, we spoke with four experts about where research efforts should be focused to tackle these diseases.
New analysis tracking the course of the COVID-19 epidemic in sub-Saharan Africa shows high country-to-country variation in disease and mortality burdens, as well as demonstrating a minimal role for climate in the spread of SARS-CoV-2 when compared with other factors, such as human mobility.
Interrogation of 1,365 near whole-genome sequences of SARS-CoV-2 variants isolated in South Africa during the first 6 months of the global pandemic reveals three major monophyletic lineages responsible for more than half of the infections in the country and underscores the value of integrating genomic surveillance methods to inform the national pandemic response.
As an increasing number of clinical decision-support systems driven by artificial intelligence progress from development to implementation, better guidance on the reporting of human factors and early-stage clinical evaluation is needed.
New personalized brain-stimulation methods for the treatment of depression and obsessive–compulsive symptoms provide hope for future treatment applications.
An increasing amount of publications are recognizing that a person’s risk of diabetes and diabetes outcomes are influenced largely by social determinants of health. This renewed understanding of disease should influence health provision and diabetes research, but will it?
In the past year, there has been more CRISPR news than the awarding of the Nobel Prize in Chemistry to Jennifer Doudna and Emmanuelle Charpentier. Gene editing has continued its forward momentum in major ways, and scientists are beginning to see results.
Unexpected direct and indirect risks of participating in clinical trials have emerged during COVID-19 that investigators and institutional review boards may not be sure how to investigate. How should existing guidance and ethical frameworks for clinical trials be applied in a pandemic setting?